Israel China Biotechnology (ICB) Ltd (ICB) — Financial Flexibility Index
Israel China Biotechnology (ICB) Ltd (ICB) has a Financial Flexibility Index of -0.26x as of June 2021. Free cash flow of ILA-1.06 Million (operating CF ILA-1.06 Million minus capex ILA0.00) represents 0% of total liabilities (ILA4.11 Million). Check ICB strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Israel China Biotechnology (ICB) Ltd Financial Flexibility Index (2015–2020)
Historical Financial Flexibility Index trend for Israel China Biotechnology (ICB) Ltd across 6 annual periods. See working capital to net assets of Israel China Biotechnology (ICB) Ltd to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Israel China Biotechnology (ICB) Ltd (2015–2020)
Year-by-year free cash flow to debt coverage for Israel China Biotechnology (ICB) Ltd. For the full company profile including market capitalisation, see Israel China Biotechnology (ICB) Ltd market capitalisation.
| Year | Flexibility Index | Free Cash Flow (ILA) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2020 | -0.55x | ILA-4.33 Million | ILA-4.34 Million | ILA7.87 Million | ▼ -26.2% |
| 2019 | -0.44x | ILA-4.22 Million | ILA-4.22 Million | ILA9.68 Million | ▲ +75.8% |
| 2018 | -1.80x | ILA-4.43 Million | ILA-4.75 Million | ILA2.46 Million | ▼ -81.1% |
| 2017 | -0.99x | ILA-2.85 Million | ILA-3.17 Million | ILA2.87 Million | ▲ +45.7% |
| 2016 | -1.83x | ILA-3.94 Million | ILA-3.94 Million | ILA2.15 Million | ▼ -16.3% |
| 2015 | -1.58x | ILA-3.77 Million | ILA-3.81 Million | ILA2.39 Million | — |